Annovis Bio Inc. (NYSE: ANVS) completed a $10 million underwritten public offering to advance its investigational drug buntanetap for neurodegenerative ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE